Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF), Innovation, Partnerships, and Leadership: A 2021 Outlook

September 13, 2021 14:10:41
  • So far in 2021, Tryp’s innovations have allowed it to position itself as a first-mover in the psychedelics space
  • The company has announced completion of psychotherapy training for the upcoming phase 2a clinical trials for specific overeating disorders
  • Tryp has also been keen on collaborating and partnering with key players in the industry, such as Calvert Labs and Gad Consulting services, the University of Michigan, and the University of Florida
  • The company also understands the value of proper leadership and, so far in 2021, it has made strategic appointments to its board of directors
Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) is a pharmaceutical company that has remained focused on developing clinical-stage compounds for diseases with high unmet medical needs. Whereas its focus is on achieving this end through accelerated regulatory pathways, the company also understands the value of innovation, forging the right partnerships, and having exemplary leadership. So far, in 2021, Tryp has made some significant strides from an innovation standpoint, ultimately positioning itself as a first-mover in the psychedelics space.  Its lead drug candidate, TRP-8802, has proven to be promising in treating fibromyalgia ( The company believes that psilocybin, a critical component in its drug formulations, can be used more effective in unmet medical needs beyond mental health, and continues to explore that. Tryp has also just announced having completed psychotherapy training and plans to initiate the upcoming phase 2a clinical trial. This trial will utilize synthetic psilocybin in combination with psychotherapy for the treatment of specific overeating disorders. The company announced that the study will be conducted at the University of Florida (“UF”) and will aim at determining the safety and efficacy of psilocybin on hyperphagia ( It is a tremendous milestone for Tryp and an indication of its commitment to innovate and find solutions to medical conditions that have not had tangible and reliable treatments. Tryp has not shied away from collaborating and partnering with other players within the industry. In August, Tryp announced its partnership with Calvert Labs and Gad Consulting Services in a move that would facilitate the trial design and execution of the phase 2b clinical trials ( Tryp also announced the appointment of Dr. Dan Clauw to its Scientific Advisory Board on the heels of a collaboration with the Chronic Pain & Fatigue Research Center at the University of Michigan Medical School for the Fibromyalgia phase 2a clinical trial earlier in the year, a critical move for the company. The initiation of clinical trials is an integral step within Tryp’s strategic initiatives in it’s commitment to utilizing the FDA’s 505(b)(2) regulatory pathway, and available third-party preclinical data to shorten the approval timelines and lower the overall cost of development programs ( Experienced drug development leadership is also a fundamental aspect of Tryp’s operations. The company’s Chief Executive Officer (“CEO”), Mr. Greg McKee, has continued to successfully Tryp as a pioneer in the psychedelics space. In 2021 alone, the company has brought Mr. McKee onto the management team and made strategic board and advisory appointments, bringing key individuals such as Robin Carhart-Harris and Dennis Langer to help steer the company towards achieving its overall goal ( So far, Tryp has managed to have an executive and advisory team that has decades of experience working in leadership positions within critical organizations in the pharmaceutical space, such as Myriad Genetics, Syntex, Dow Chemical, Jubilant, Unigene Laboratories, and Genzyme ( Together, these leaders help push Tryp’s agenda and offer solutions to issues with high unmet medical needs. 2021 has been an excellent year for Tryp, as the company has made incredible strides to further its mission. It is a testament to what can be achieved once a company has the right leadership, forges the right partnerships, and continues to innovate with its products and services. For more information, visit the company’s website at NOTE TO INVESTORS: The latest news and updates relating to TRYPF are available in the company’s newsroom at About PsychedelicNewsWire PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics. To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only) For more information please visit Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: Do you have questions or are you interested in working with PNW? Ask our Editor PsychedelicNewsWire (PNW) San Francisco, California 415.949.5050 Office PsychedelicNewsWire is part of the InvestorBrandNetwork.